Cargando…

Renal Cell Cancer: What Can We Learn from Pre-Operative Studies?

Detalles Bibliográficos
Autores principales:	Fisher, Rosalie, Larkin, James
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Research Foundation 2011
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356090/ https://www.ncbi.nlm.nih.gov/pubmed/22655250 http://dx.doi.org/10.3389/fonc.2011.00051

Ejemplares similares

Inter and Intratumour Heterogeneity: A Barrier to Individualized Medical Therapy in Renal Cell Carcinoma?
por: Fisher, Rosalie, et al.
Publicado: (2012)

DIPG in Children – What Can We Learn from the Past?
por: Vanan, Magimairajan Issai, et al.
Publicado: (2015)

What can we learn from more than 1,000 Brazilian patients at risk of hereditary cancer?
por: Leite, Ana Carolina Rathsam, et al.
Publicado: (2022)

Polyorchidism and testicular malignancy, what can we learn: A case report
por: Nurfajri, Derri Hafa, et al.
Publicado: (2021)

Observation as a treatment strategy for advanced renal cell carcinoma—a call for prospective validation
por: Fisher, Rosalie, et al.
Publicado: (2012)

Lymphopenia in Esophageal Cancer: What Have We Learned?
por: Wang, Jia-Lin, et al.
Publicado: (2021)

Ongoing Remission Nineteen Years after High-dose Chemotherapy for Oligometastatic Breast Cancer; What Can We Learn from this Patient?
por: Steenbruggen, Tessa G, et al.
Publicado: (2015)

Paving the Road for Modern Particle Therapy – What Can We Learn from the Experience Gained with Fast Neutron Therapy in Munich?
por: Specht, Hanno M., et al.
Publicado: (2015)

Editorial: Prostate Cancer: What We Know and What We Would Like to Know
por: Taverna, Gianluigi, et al.
Publicado: (2015)

Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity
por: Fisher, Rosalie, et al.
Publicado: (2011)

Lessons learned from COVID-19 for clinical research operations in Italy: what have we learned and what can we apply in the future?
por: Cagnazzo, Celeste, et al.
Publicado: (2020)

Surgery: To what extent can we operate?
por: Kakeji, Yoshihiro
Publicado: (2018)

Brain Tumor Immunotherapy: What have We Learned so Far?
por: Van Gool, Stefaan Willy
Publicado: (2015)

Modeling WWOX Loss of Function in vivo: What Have We Learned?
por: Tanna, Mayur, et al.
Publicado: (2018)

Pre-treatment expectations of patients with spinal metastases: what do we know and what can we learn from other disciplines? A systematic review of qualitative studies
por: Gal, R., et al.
Publicado: (2020)

Cancer Chemoprevention: Classic and Epigenetic Mechanisms Inhibiting Tumorigenesis. What Have We Learned So Far?
por: de Melo, Fabiana Henriques Machado, et al.
Publicado: (2018)

Roles of microRNAs in Ovarian Cancer Tumorigenesis: Two Decades Later, What Have We Learned?
por: Alshamrani, Ali A.
Publicado: (2020)

MRD Tailored Therapy in AML: What We Have Learned So Far
por: Ngai, Lok Lam, et al.
Publicado: (2021)

What Can We Learn from Medical Whistleblowers?
por: Lenzer, Jeanne
Publicado: (2005)

What can we learn from Plausible Values?
por: Marsman, Maarten, et al.
Publicado: (2016)

What can we learn from honey bees?
por: Schwartzman, Julia A
Publicado: (2021)

Aging: What We Can Learn From Elephants
por: Chusyd, Daniella E., et al.
Publicado: (2021)

Neurosecretion: what can we learn from chromaffin cells
por: Neher, Erwin
Publicado: (2017)

Cancer Microenvironment: What Can We Learn from the Stem Cell Niche
por: Lacina, Lukas, et al.
Publicado: (2015)

What can we learn from publishing endoscopy trial protocols?
por: Koutsoumpas, Andreas, et al.
Publicado: (2016)

Immune-checkpoint inhibitors for glioblastoma: what have we learned?
por: Omuro, Antonio
Publicado: (2022)

Jets: what we can still learn....
por: Humpert, Benedikt, et al.
Publicado: (1984)

Recent advances in the field of renal potassium excretion: what can we learn from potassium channels?
por: Giebisch, G. H.
Publicado: (1997)

Transarterial Chemoembolization Combined With Tyrosine Kinase Inhibitors for Intermediate‐Stage Hepatocellular Carcinoma, What Else Can We Do?
por: Deng, Jun, et al.
Publicado: (2022)

The Role of Contactin 1 in Cancers: What We Know So Far
por: Liang, Yumei, et al.
Publicado: (2020)

What can we learn from geographical comparisons of childhood cancer survival?
por: Pritchard-Jones, K, et al.
Publicado: (2007)

Prostate cancer screening: what can we learn from randomised trials?
por: Auvinen, Anssi
Publicado: (2018)

What can we learn from cancer of unknown primary in canine oncology?
por: Khazzaka, Aline, et al.
Publicado: (2020)

Skin Cancer Microenvironment: What We Can Learn from Skin Aging?
por: D’Arino, Andrea, et al.
Publicado: (2023)

What can we learn from drug marketing efficiency?
por: Kao, David P
Publicado: (2008)

What we can learn from the next generation of experiments
por: Ross, Graham G
Publicado: (1981)

Neuroblastoma Mass Screening—What Can We Learn From It?
por: Katanoda, Kota
Publicado: (2016)

What can we learn from neonates with COVID-19?
por: Xiao, Tian-Tian, et al.
Publicado: (2020)

What can we learn from the islet of Joslin Medalists?
por: Yagihashi, Soroku
Publicado: (2020)

What Can We Learn from Sex Differences in MS?
por: Coyle, Patricia K.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_71du0ia4o83fu7etp409d0dbli